JUPITER LIFE LINE HOSPITALS
|
|
BOM : 543980     NSE : JLHL     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Apr 11,2025 |
Price(EOD): ₹ 1,451.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
MCap: ₹ 9,523.15 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
JUPITER LIFE LINE HOSPITALS | -6.8% | -2.3% | 15.9% |
MAX HEALTHCARE INSTITUTE | -4.1% | 13% | 37.2% |
APOLLO HOSPITALS ENTERPRISE | 0.8% | 10.1% | 8.3% |
FORTIS HEALTHCARE | 0.1% | 4.6% | 50.7% |
GLOBAL HEALTH | 2.9% | 5% | -11.2% |
NARAYANA HRUDAYALAYA | 1.4% | 7.3% | 27.4% |
KRISHNA INSTITUTE OF MEDICAL SCIENCES | 3.6% | 19.7% | 47.5% |
DR LAL PATHLABS | 7.4% | 3.8% | 16.4% |
ASTER DM HEALTHCARE | 3.9% | 18.5% | 1.7% |
FUNDAMENTAL ANALYSIS OF JUPITER LIFE LINE HOSPITALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF JUPITER LIFE LINE HOSPITALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
49.09
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 193.89 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 8.14
P/B Calculated based on Book Value of Rs 1,169.04 Cr
[Latest Year - Mar2024 - Consolidated Results ] 7.8
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,220.83 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
528% 582% -11% |
SHARE PRICE MOMENTUM OF JUPITER LIFE LINE HOSPITALS
JUPITER LIFE LINE HOSPITALS vs SENSEX
DEBT OF JUPITER LIFE LINE HOSPITALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0.64 0.98 0.54 |
0 1.28 1.7 0.99 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF JUPITER LIFE LINE HOSPITALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF JUPITER LIFE LINE HOSPITALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-0.6% 0.03% -3.41% 1.95% |
17.62% 21.27% 14.59% 20.26% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
JUPITER LIFE LINE HOSPITALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE HEALTHCARE | -3.5% | 2.1% | 13.7% |
BSE SMALLCAP | -3.6% | 0.4% | -0.5% |
BSE MIDSMALLCAP | -3.6% | 0.7% | -0.9% |
BSE ALLCAP | -4.4% | -0.7% | -1.9% |
You may also like the below Video Courses
FAQ about JUPITER LIFE LINE HOSPITALS
Is JUPITER LIFE LINE HOSPITALS good for long term investment?
As on Apr 11,2025, the Fundamentals of JUPITER LIFE LINE HOSPITALS look Strong and hence it may be good for long term investment! See Financial Performance of JUPITER LIFE LINE HOSPITALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is JUPITER LIFE LINE HOSPITALS UnderValued or OverValued?
As on Apr 11,2025, JUPITER LIFE LINE HOSPITALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of JUPITER LIFE LINE HOSPITALS ?
As on Apr 11,2025, the Intrinsic Value of JUPITER LIFE LINE HOSPITALS is Rs. 231.10 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 231.10
Fair Value [Median EV / Sales Model] : Rs. 212.84
Fair Value [Median Price / Sales Model] : Rs. 1,632.84
Estimated Median Fair Value of JUPITER LIFE LINE HOSPITALS : Rs. 231.10
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.